Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective hard but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last few shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the business.

Irony of irony, the bad viewpoint of mine of the business enterprise has grown steadily, though the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the expertise as well as linked intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) along with the first brand new drug application approval ($five million), and even royalty payments of 5 % of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this individual remedy as well as a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy in dozens of indications.

Its opening banner on its site (below) shows an active business with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple presentations.

Might it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really beginning of my interest in this particular business. Judging by the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or even some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *